Proton-pump inhibitors (PPIs) can alter the pharmacodynamic profile of clopidogrel and reduce its platelet-inhibitory effects. Ho and colleagues have reported that concurrent use of PPIs and clopidogrel leads to in an increase in adverse cardiovascular outcomes. In this article we discuss the clinical implications of the interaction between these two drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Angiolillo, D. J. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49, 1505–1516 (2007).
Gilard, M. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51, 256–260 (2008).
Ho, P. M. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301, 937–944 (2009).
Dunn, S. et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. [Abstract 3999]. Circulation 118, S_815 (2008).
Bhatt, D. L. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am. J. Gastroenterol. 103, 2890–2907 (2008).
Juurlink, D. N. et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180, 713–718 (2009).
Mega, J. L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354–362 (2009).
Siller-Matula, J. M. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 157, 148.e1–5 (2009).
Small, D. S. et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol. 48, 475–484 (2008).
Eikelboom, J. W. et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114, 774–782 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. J. Angiolillo has received honoraria for lectures from Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, and Sanofi Aventis. He has received Advisory Board honoraria from Accumetrics, Arena Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Medicure, Novartis, Portola, Sanofi-Aventis, and The Medicines Company. He has received research grants from Accumetrics, AstraZeneca, Daiichi Sankyo, Eli Lilly, Eisai, GlaxoSmithKline, Otsuka, Portola, Schering-Plough, and The Medicines Company. J. L. Ferreiro declares no competing interests.
Rights and permissions
About this article
Cite this article
Ferreiro, J., Angiolillo, D. Clopidogrel plus PPIs—a dangerous combination?. Nat Rev Cardiol 6, 392–394 (2009). https://doi.org/10.1038/nrcardio.2009.60
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2009.60
